文献速递甲状腺核医学肿瘤 PET/CT核素与放射性配体治疗

未分化甲状腺癌患者中显著的99mTc-FAPI-46摄取:诊疗一体化领域有希望的一步

Remarkable 99mTc-FAPI-46 Uptake in a Patient With Anaplastic Thyroid Carcinoma: A Promising Step in Theranostic Field.
PubMed 文献 · Clin Nucl Med · 2025-03-11

本文报道一例未分化甲状腺癌患者为评估转移病灶而行99mTc-FAPI-46 SPECT/CT,发现包括钙化甲状腺肿块、纵隔淋巴结、双肺、肝脏、多处骨骼及膝关节假体周围在内的多个转移灶均有显著FAPI摄取,患者因此被考虑为FAP靶向放射性核素治疗的候选者。

要点

  • 未分化甲状腺癌患者的99mTc-FAPI-46 SPECT/CT显示多个转移灶有显著摄取。
  • 摄取部位包括钙化甲状腺肿块、纵隔淋巴结、双肺、肝脏、骨骼及膝关节假体周围。
  • 基于病灶显著摄取,患者被考虑为FAP靶向放射性核素治疗的候选者。

核心结论

  • FAP靶向放射性核素是癌症诊断和治疗(诊疗一体化)中有希望的一步,但仍属研究中的课题。
  • 本病例中多个转移灶显示显著99mTc-FAPI-46摄取,患者被考虑为FAP靶向放射性核素治疗的候选者。

研究设计与样本

  • 本文为一例未分化甲状腺癌患者的病例报告,患者接受99mTc-FAPI-46 SPECT/CT以评估转移性疾病。

主要发现

  • 99mTc-FAPI-46 SPECT/CT发现多个转移部位有显著摄取。
  • 恶性FAPI摄取见于大的钙化甲状腺肿块、纵隔淋巴结、双肺、肝脏、少数骨骼部位及膝关节假体周围。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein (FAP)-targeted radionuclides are known as a promising step in cancer diagnosis and treatment (theranostic), although it is still a subject under investigation. We present a patient with anaplastic thyroid carcinoma who underwent 99mTc-FAPI-46 SPECT/CT for the evaluation of metastatic disease. Several metastatic sites were found with considerable 99mTc-FAPI-46 uptake. Malignant FAPI uptake was observed in the large calcified thyroid mass, mediastinal lymph node, both lungs, liver, few skeletal sites, and around knees prostheses. Given the notable uptake of lesions, the patient was considered as a candidate for FAP-targeted radionuclide therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ghahraman M, Sahafi P, Samadi MH, et al. Remarkable 99mTc-FAPI-46 Uptake in a Patient With Anaplastic Thyroid Carcinoma: A Promising Step in Theranostic Field. Clin Nucl Med. 2025. PMID: 40065418. doi:10.1097/RLU.0000000000005746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。